Key Details
Price
$45.70Last Dividend
$2.05Annual Revenue
$230.44 MAnnual ROE
16.94%Beta
0.63Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
Nov 15, 2024Next split:
N/ARecent split:
Oct 01, 1980Analyst ratings
Recent major analysts updates
Screeners with CET included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
The shareholders of Fingerprint Cards AB (publ), reg. no. 556154-2381 (the “Company” or “Fingerprints”), are hereby invited to attend an Extraordinary General Meeting (the “EGM” or “Meeting”) to be held at 10:00 a.m. (CET) on 17 January 2025, at Gernandt & Danielsson Advokatbyrå, Hamngatan 2, 111 47, Stockholm, Sweden. The entrance to, and registration for, the Meeting will open at 9:30 a.m (CET).
NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET) announced today that the price at which Common Stock will be issued in payment of the $2.05 per share distribution payable on December 20, 2024 is $47.41 per share. This price is the arithmetic average of the daily volume weighted average price (“VWAP”) of the Corporation's Common Stock for each of the last three trading days ending on and including December 4, 2024, rounded to two decimal places. The distribution wa.
United Overseas Bank's focus on Southeast Asia and acquisition of Citi's retail business enhance growth prospects, offering a 5% dividend yield and steady earnings growth. Despite the lowest CET1 CAR among peers, UOB's fully phased-in CET1 CAR of 15.2% aligns with peers, indicating potential for increased shareholder returns. UOB's current valuation is fair, with potential for a premium due to excess capital and the prospect of increased shareholder distributions.
Central Securities Corporation offers a 4.86% yield and has outperformed the S&P 500 over 30 years, making it attractive for long-term capital appreciation. The fund's portfolio is diversified, focusing on undervalued equities, and is less concentrated in technology compared to the S&P 500. Trading at a 16.62% discount to NAV, Central Securities Corporation provides a cost-effective investment with a low expense ratio of 0.53%.
REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.
NEW YORK--(BUSINESS WIRE)--Central Securities Corporation (NYSE American: CET), a closed-end investment company, today released its Report to Stockholders for the nine months ended September 30, 2024. Figures as of September 30, 2024 compared with those of one year ago, are as follows: September 30, September 30, 2024 2023 Net assets per common share $56.17 $43.63 Net assets $1,594,454,696 $1,218,907,463 Shares outstanding 28,387,828 27,939,274 Additional details are a.
Invitation to Q3 2024 Presentation 15 November BW Offshore will release its Q3 2024 results on Friday 15 November at 07:30 CET. A conference call followed by Q&A will be hosted by CEO Marco Beenen and CFO Ståle Andreassen the same day at 14:00 CET.
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) will publish its financial and operating results and related management's discussion and analysis for the three and nine months ended September 30, 2024, on Tuesday, November 5, 2024 at 07:30 CET, followed by an audiocast at 09:00 CET.
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET (8:30 AM ET) Regulated information - Inside information October 31, 2024 7:00AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2024 financial results and provided a business update. “We delivered significant patient impact with VYVGART over the quarter, expanding our gMG footprint and delivering innovation to CIDP patients three months into launch,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
FAQ
- What is the primary business of Central Securities?
- What is the ticker symbol for Central Securities?
- Does Central Securities pay dividends?
- What sector is Central Securities in?
- What industry is Central Securities in?
- What country is Central Securities based in?
- When did Central Securities go public?
- Is Central Securities in the S&P 500?
- Is Central Securities in the NASDAQ 100?
- Is Central Securities in the Dow Jones?
- When does Central Securities report earnings?